Targeting of an Anti-Metastatic and Anti-Angiogenic Compound to Breast Tumors
Abstract
Our laboratory is studying anastellin, a fragment of fibronectin that inhibits angiogenesis, tumor growth and metastasis in vivo. By fusing anastellin with peptides that home to specific vascular sites in angiogenic vasculature, I am testing whether the concentration of anastellin at the angiogenic endothelium can be increased, and whether that would improve the anti-angiogenic activity of anastellin. I have found that targeting anastellin to angiogenic blood vessel endothelium in vivo does not improve the efficacy of anastellin. However, in contrast, targeting anastellin to lymphangiogenic vessels has a significant inhibiting effect on the development of lymphatic vasculature. These findings are interesting, because eliminating tumor lymphatics is a key step in inhibiting tumor metastasis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2003
- Accession Number
- ADA417959
Entities
People
- Maria Akerman
Organizations
- Sanford Burnham Prebys Medical Discovery Institute